For decades, the standard model of medical succession was the earn-in. A younger physician joined a practice, worked hard for low pay for a few years, and eventually bought out the senior partner using future cash flow.

In the MSO era, that path has changed.

Now, when a practice is acquired, the successor physician is often stepping into a role that is structurally different from the one the founder held. The founder was an owner-operator. The successor is often an employed clinical leader with significant responsibility but ambiguous authority.

This transition is often pitched as an opportunity to take the reins or lead the next chapter. Without specific structural protections, it often becomes a mismatch: high accountability, high workload, and low decision-making power.

A viable successor role requires alignment between authority, insurance, and economics.

The Risk of Responsibility Without Authority

The most common point of failure for successor physicians is the gap between accountability and control.

In many post-transaction structures, the senior founder steps back into a reduced clinical role or a purely advisory role. The MSO looks to the younger successor physician to serve as the Medical Director or Clinical Lead.

If this title comes with the responsibility to sign off on charts, supervise mid-level providers, and maintain accreditation, but without the authority to hire or fire staff, set schedules, or enforce protocols, the physician is carrying accountability without the tools to manage it.

To avoid this, the role must be scoped in writing, not just in conversation.

What to Confirm Before Signing

If you are evaluating a clinical leadership role inside a platform, or you are an associate being asked to step up as a founder exits, there are six structural points that deserve clarity.

The first is governance and authority definition. If you are the Medical Director, you need to know what you can actually direct. Do you have veto power over clinical hires? Do you have the final say on patient safety protocols? The agreement should explicitly state which decisions require your approval. Responsibility without authority is risk.

The second is supervision and coverage clarity. Platforms often rely on leverage through nurse practitioners, physician assistants, and optometrists to scale. As the clinical lead, you are often the supervising physician of record. You need to know whether there is a hard cap on how many providers you supervise and whether you are compensated specifically for this administrative burden. Be cautious with open-ended supervision language like "and other duties as assigned" unless it is paired with clear caps, compensation, and scope.

The third is insurance and indemnity alignment. If the MSO makes a non-clinical operational error that affects patient care, such as failing to send a referral or creating availability issues with critical supplies, the clinical leader may bear regulatory scrutiny depending on the facts, documentation, and structure. You need to know whether there is clear indemnity for non-clinical operational errors and whether the agreement matches how risk is actually allocated day to day. You should also confirm whether the malpractice policy is individual or shared and whether it includes tail coverage if you leave.

The fourth is workload expectations. When a founder slows down, the volume has to go somewhere, and it often flows to the successor. You need to know whether your clinical volume is capped. If you are taking on administrative leadership, you need to know whether your clinical template is reduced to accommodate it, or whether you are expected to do administrative work on nights and weekends.

The fifth is compensation clarity and adjustment logic. Successor compensation is often a mix of base, productivity, and sometimes phantom equity or profit sharing. You need to know whether your compensation drops if the platform struggles. If any portion of your compensation is tied to EBITDA or margin, you need to know whether you have control over the expenses that drive that number. Avoid compensation models tied to metrics you cannot influence.

The sixth is the year one predictability plan. You need to know what happens if the founder leaves earlier than expected. Is there a transition plan documented covering call coverage, supervision expectations, scheduling template, and leadership time allocation? Who absorbs the founder's complex cases? Predictability matters more than reassurance.

Moving from Employee to Stakeholder

A successor physician does not need to be an equity owner to think like a stakeholder. But they do need a contract that treats them as a partner, not just a yield-generating asset.

The goal is to ensure that the physician who is staying for the long haul has the tools, protection, and authority to practice medicine safely.

When the deal is structured correctly, the successor gets a stable platform to build a career, and the MSO gets a committed clinical leader. When it is structured poorly, the relationship often becomes unstable within the first 12 to 24 months.

How Verdira Approaches This

Clinical decisions remain with physicians. MSO scope is clearly defined in writing and tied to real services. Governance is clarified before signing so expectations remain stable after close. We build long-duration platforms and do not operate on forced exits.

If you are evaluating an MSO partnership or successor role and want to sanity-check structure and expectations, we are open to thoughtful conversations.

This article is for general educational purposes and is not legal advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're looking for a different model, or you know a colleague who is, contact us today.

Contact info@verdira.com 307-381-3734 verdira.com